The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2534-2546

  Morelli, Maria Beatrice ^a   Offidani, Massimo ^b   Alesiani, Francesco ^c   Discepoli, Giancarlo ^b   Liberati, Sonia ^d   Olivieri, Attilio ^b   Santoni, Matteo ^a   Santoni, Giorgio ^a   Leoni, Pietro ^b   Nabissi, Massimo ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c San Severino Marche MC   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

bortezomib; cannabidiol; multiple myeloma; transient receptor potential vanilloid type 2

Indexed keywords

BORTEZOMIB; CANNABIDIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SYNDECAN 1; VANILLOID RECEPTOR 2;

ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; FLUORESCENCE IN SITU HYBRIDIZATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BORTEZOMIB; CANNABIDIOL; MULTIPLE MYELOMA; TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 2;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CANNABIDIOL; CELL CYCLE; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MULTIPLE MYELOMA; NF-KAPPA B; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRPV CATION CHANNELS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84896391802     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28591     Document Type: Article

References (46)

1. Rajkumar SV,. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 57-65.
2. Katzel JA, Hari P, Vesole DH,. Multiple myeloma: charging toward a bright future. CA Cancer J Clin 2007; 57: 301-18.
3. Hideshima T, Anderson KC,. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol 2011; 94: 344-54.
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.
5. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17.
6. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-30.
7. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-44.
8. Ghosh S, Karin M,. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 Suppl: S81-96.
9. Hayden MS, Ghosh S,. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-62.
10. Demchenko YN, Glebov OK, Zingone A, et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010; 115: 3541-52.
11. Lonial S, Kaufman JL,. The era of combination therapy in myeloma. J Clin Oncol 2012; 30: 2434-36.
12. Munshi NC, Avet-Loiseau H,. Genomics in multiple myeloma. Clin Cancer Res 2011; 17: 1234.
13. Caterina MJ, Rosen TA, Tominaga M, et al. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999; 398: 436-41.
14. Santoni G, Morelli MB, Santoni M, et al. New deals on the transcriptional and post-transcriptional regulation of TRP channel target genes during the angiogenesis of glioma. J Exp Integr Med 2011; 1: 221-34.
15. Santoni G, Farfariello V, Amantini C,. TRPV channels in tumor growth and progression. Adv Exp Med Biol 2011; 704: 947-67.
16. Nabissi M, Morelli MB, Amantini C, et al. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis 2010; 31: 794-03.
17. Nabissi M, Morelli MB, Santoni M, et al. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 2013; 34: 48-57.
18. Morelli MB, Nabissi M, Amantini C, et al. The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. Int J Cancer 2012; 131: E1067-77.
19. Santoni G, Farfariello V, Liberati S, et al. The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. Front Immunol 2013; 4: 34.
20. Fabris S, Todoerti K, Mosca L, et al. Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. Genes Chromosomes Cancer 2007; 46: 1109-18.
21. Qin N, Neeper MP, Liu Y, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 2008; 28: 6231-8.
22. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163: 1479-94.
23. Yamada T, Ueda T, Shibata Y, et al. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology 2010; 76:509. e1-7.
24. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol-recent advances. Chem Biodivers 2007; 4: 1678-92.
25. McKallip RJ, Jia W, Schlomer J, et al. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 2006; 70: 897-08.
26. Gallily R, Even-Chena T, Katzavian G, et al. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 2003; 44: 1767-73.
27. Chou TC,. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2007; 59: 124.
28. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-28.
29. Morgan GJ, Walker BA, Davies FE,. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-48.
30. Torres S, Lorente M, Rodríguez-Fornés F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011; 10: 90-03.
31. Feng R, Oton A, Mapara MY, et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-97.
32. De Petrocellis L, Di Marzo V,. Non-CB1, non-CB2 receptors for endocannabinoids, #plant |cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 2010; 5: 103-21.
33. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007; 138: 783-91.
34. Li ZW, Chen H, Campbell RA, et al. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008; 15: 391-99.
35. Shi L, Wang S, Zangari M, et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010; 1: 22-33.
36. Dai Y, Chen S, Pei XY, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008; 112: 2439-49.
37. Chesi M, Kuehl WM, Bergsagel PL,. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol 2000; 11: 131-35.
38. Frost P, Shi Y, Hoang B, et al. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther 2009; 8: 83-93.
39. Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116: 4560-68.
40. Harvey RD, Lonial S,. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 2007; 3: 639-47.
41. Chauhan D, Hideshima T, Anderson KC,. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006; 95: 961-65.
42. Que W, Chen J, Chuang M, et al. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 2012; 120: 195-03.
43. Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010; 149: 537-49.
44. Sen R,. Control of B lymphocyte apoptosis by the transcription factor NF-kappaB. Immunity 2006; 25: 871-83.
45. Lorch JH, Thomas TO, Schmoll HJ,. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 2007; 67: 727-34.
46. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80.